NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ALGS

Aligos Therapeutics Inc

Jul 01 • 03:52PM ET

7.34

Dollar change +0.12
Percentage change 1.73	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD ARWR RAPT NBIX ABUS AKRO BCRX AMLX ALT

| Held by: VTI VXF SCHA AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-17.45	Insider Own	31.01%	Shs Outstand	5.31M	Perf Week	-10.98%
Market Cap	44.85M	Forward P/E	-	EPS next Y	-8.89	Insider Trans	0.00%	Shs Float	4.22M	Perf Month	38.66%
Enterprise Value	-85.25M	PEG	-	EPS next Q	-2.36	Inst Own	53.75%	Short Float	12.85%	Perf Quarter	-11.09%
Income	-53.26M	P/S	13.72	EPS this Y	53.69%	Inst Trans	1.70%	Short Ratio	3.47	Perf Half Y	-83.09%
Sales	3.27M	P/B	0.39	EPS next Y	8.28%	ROA	-38.23%	Short Interest	0.54M	Perf YTD	-81.59%
Book/sh	19.04	P/C	0.33	EPS next 5Y	24.44%	ROE	-60.44%	52W High	46.80 -84.33%	Perf Year	-22.46%
Cash/sh	22.56	P/FCF	-	EPS past 3/5Y	- -	ROIC	-44.08%	52W Low	3.76 95.08%	Perf 3Y	-77.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-3.27% -	Gross Margin	34.50%	Volatility	11.57% 11.49%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-26.07	EPS Y/Y TTM	-	Oper. Margin	-2640.70%	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.56	Sales Y/Y TTM	-76.29%	Profit Margin	-1628.75%	RSI (14)	52.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.56	EPS Q/Q	62.14%	SMA20	-0.24%	Beta	2.78	Target Price	85.25
Payout	-	Debt/Eq	0.07	Sales Q/Q	-68.46%	SMA50	18.39%	Rel Volume	0.27	Prev Close	7.21
Employees	70	LT Debt/Eq	0.04	Earnings	May 06 BMO	SMA200	-52.22%	Avg Volume	156.16K	Price	7.34
IPO	Oct 16, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	29.14% -37.80%	Trades		Volume	41,261	Change	1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Initiated	H.C. Wainwright	Buy	$75
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $3
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$2.50 → $3
Mar-23-22	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $4
Jan-07-22	Downgrade	JP Morgan	Overweight → Neutral	$30 → $12
Jan-06-22	Downgrade	Jefferies	Buy → Hold
Sep-09-21	Initiated	SVB Leerink	Outperform	$29
May-17-21	Resumed	Piper Sandler	Overweight	$47
Nov-10-20	Initiated	Piper Sandler	Overweight	$35
Nov-10-20	Initiated	JP Morgan	Overweight	$33
Nov-10-20	Initiated	Jefferies	Buy	$26
Nov-10-20	Initiated	Cantor Fitzgerald	Overweight	$28

Show Previous Ratings

Jun-18-25 08:00AM	Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) (GlobeNewswire) +11.16%
Jun-13-25 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 08:00AM	Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal (GlobeNewswire)
May-16-25 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
May-08-25 08:00AM	Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 (GlobeNewswire) +11.70%
May-06-25 09:35AM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -9.31%
08:00AM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:40AM	UPS downgraded, ServiceNow upgraded: Wall Street's top analyst calls (The Fly) +8.15%
Apr-29-25 08:30AM	Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-23-25 04:05PM	Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 (GlobeNewswire) +8.77%
Mar-26-25 08:00AM	Aligos Therapeutics Presents Positive Data at APASL 2025 (GlobeNewswire) -10.14%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) +11.28%
08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-25 09:25AM	Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -19.55%
08:00AM	Loading…
08:00AM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire) -14.05%
Feb-12-25 07:00AM	Aligos Therapeutics Announces $105 Million Private Placement Financing (GlobeNewswire) -19.25%
Jan-13-25 04:32PM	Here's Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing (Insider Monkey) -12.49%
Dec-13-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 08:00AM	Aligos Therapeutics to Present at Investor Conferences in December (GlobeNewswire)
Nov-19-24 01:30PM	Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 (GlobeNewswire) -8.05%
Nov-06-24 06:05PM	Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.10%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 04:05PM	Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 (GlobeNewswire)
Oct-15-24 09:00AM	Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.60%
Oct-01-24 08:00AM	Aligos Therapeutics Appoints David Perry as Vice President of Business Development (GlobeNewswire)
Sep-30-24 08:00AM	Aligos Therapeutics to Present at Investor Conferences in October (GlobeNewswire) +7.71%
08:00AM	Loading…
Sep-24-24 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer (GlobeNewswire)
Sep-20-24 04:52AM	Aligos reports positive data from Phase IIa MASH treatment trial (Clinical Trials Arena) -10.22%
Sep-19-24 08:00AM	Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH (GlobeNewswire) -28.11%
Sep-18-24 05:00PM	Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 (GlobeNewswire)
Sep-13-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49%
Sep-10-24 09:40AM	Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? (Zacks) -29.03%
Aug-21-24 09:55AM	How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% (Zacks) -5.04%
Aug-15-24 09:00AM	Aligos Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Aug-09-24 12:00PM	What Makes Aligos Therapeutics (ALGS) a New Buy Stock (Zacks)
Aug-08-24 04:05PM	Aligos Therapeutics Strengthens Board with Two New Independent Directors (GlobeNewswire)
Aug-07-24 12:53PM	Hepatitis B market is ripe for treatment development, says Aligos CEO (Pharmaceutical Technology) +21.95%
Aug-06-24 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 04:05PM	Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-22-24 09:00AM	Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. (GlobeNewswire) +11.08%
Jul-10-24 08:00AM	Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB (GlobeNewswire) +7.89%
Jun-05-24 02:30AM	Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 (GlobeNewswire)
Jun-04-24 09:55AM	Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-22-24 04:05PM	Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 (GlobeNewswire) -8.95%
May-21-24 08:00AM	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH (GlobeNewswire)
May-16-24 09:35AM	After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS) (Zacks)
May-07-24 09:56PM	ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 04:05PM	Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study (GlobeNewswire)
08:00AM	Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD (GlobeNewswire)
Apr-09-24 08:00AM	Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)
Mar-27-24 09:55AM	Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:00AM	Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies (GlobeNewswire)
Mar-18-24 08:00AM	Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)
Mar-12-24 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:05PM	Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Feb-26-24 08:00AM	Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) +21.33%
Feb-20-24 08:00AM	Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments (GlobeNewswire) -6.18%
Jan-05-24 09:40AM	Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-07-23 04:05PM	Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) (GlobeNewswire) -10.77%
Nov-24-23 10:26AM	13 Stocks Insiders are Buying Now (Insider Monkey) +5.29%
Nov-20-23 04:05PM	Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference (GlobeNewswire) -9.17%
09:10AM	Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today? (InvestorPlace)
Nov-13-23 08:00AM	Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile (GlobeNewswire) -14.13%
Nov-10-23 08:05AM	Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg) (GlobeNewswire) -9.26%
Nov-07-23 08:00AM	Aligos Therapeutics to Present Multiple Posters at AASLD's The Liver Meeting 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR- Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company's Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C) (GlobeNewswire)
Nov-03-23 04:30PM	Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data (GlobeNewswire)
Nov-02-23 06:57PM	Aligos Therapeutics Inc (ALGS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-30-23 01:06PM	Hedge Fund and Insider Trading News: Joseph Edelman, Ken Griffin, Seth Klarman, Two Sigma Advisors, Sculptor Capital Management, Aligos Therapeutics Inc (ALGS), The Progressive Corporation (PGR), and More (Insider Monkey)
Oct-26-23 04:05PM	Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023 (GlobeNewswire)
Oct-25-23 08:00AM	Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting 2023 (GlobeNewswire)
Oct-23-23 08:00AM	Aligos Therapeutics Announces $92 Million Private Placement Financing (GlobeNewswire) -21.52%
Oct-03-23 07:30AM	Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558 (GlobeNewswire)
Sep-21-23 07:30AM	Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009 (GlobeNewswire)
Aug-03-23 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-27-23 04:05PM	Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023 (GlobeNewswire)
Jul-19-23 07:30AM	Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009 (GlobeNewswire)
Jun-21-23 04:30PM	Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Jun-07-23 07:30AM	Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Jun-05-23 06:09AM	We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-24-23 05:26PM	Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-12-23 05:05PM	Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos Oligonucleotide Platform for the Treatment of Liver Diseases (GlobeNewswire) +19.27%
May-04-23 07:25PM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.82%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:05PM	Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 (GlobeNewswire) +8.41%
Apr-17-23 06:51AM	Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 30% Dip In Price Shows Sentiment Is Matching Revenues (Simply Wall St.)
Apr-11-23 06:50PM	Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Mar-29-23 04:05PM	Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference (GlobeNewswire) -6.73%
Mar-09-23 06:25PM	Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.21%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023 (GlobeNewswire) -7.01%
Feb-16-23 08:00AM	Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (GlobeNewswire)

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALGS

Aligos Therapeutics Inc

Upgrade your FINVIZ experience